Menu

Whether millions of people will be able to afford one of the hot new weight-loss drugs could hinge on whether they cure the sleep apnea of people like Damon Sedgwick.

Sedgwick, a technology business analyst in Sydney, enrolled in a clinical trial in 2022 to test whether taking weekly injections of Eli Lilly’s anti-obesity drug Zepbound would alleviate the sleep apnea that had plagued his nights for years.

Scroll to Top